DNB Asset Management AS Decreases Stock Holdings in Thermo Fisher Scientific Inc. $TMO

DNB Asset Management AS cut its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 8.9% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 126,849 shares of the medical research company’s stock after selling 12,465 shares during the quarter. DNB Asset Management AS’s holdings in Thermo Fisher Scientific were worth $61,524,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of the business. Highline Wealth Partners LLC raised its position in shares of Thermo Fisher Scientific by 126.9% during the 3rd quarter. Highline Wealth Partners LLC now owns 59 shares of the medical research company’s stock valued at $29,000 after buying an additional 33 shares in the last quarter. Capital A Wealth Management LLC raised its position in Thermo Fisher Scientific by 825.0% during the second quarter. Capital A Wealth Management LLC now owns 74 shares of the medical research company’s stock valued at $30,000 after purchasing an additional 66 shares during the period. Cloud Capital Management LLC purchased a new position in shares of Thermo Fisher Scientific in the 3rd quarter worth approximately $31,000. Howard Hughes Medical Institute purchased a new stake in Thermo Fisher Scientific during the 2nd quarter valued at $33,000. Finally, Elevation Wealth Partners LLC lifted its position in Thermo Fisher Scientific by 35.1% in the third quarter. Elevation Wealth Partners LLC now owns 77 shares of the medical research company’s stock worth $37,000 after buying an additional 20 shares during the last quarter. Institutional investors own 89.23% of the company’s stock.

Insider Transactions at Thermo Fisher Scientific

In related news, EVP Frederick M. Lowery sold 6,913 shares of the firm’s stock in a transaction dated Monday, December 1st. The stock was sold at an average price of $597.68, for a total transaction of $4,131,761.84. Following the sale, the executive vice president owned 14,367 shares of the company’s stock, valued at $8,586,868.56. This trade represents a 32.49% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, COO Michel Lagarde sold 32,000 shares of the business’s stock in a transaction dated Wednesday, December 3rd. The stock was sold at an average price of $583.39, for a total transaction of $18,668,480.00. Following the completion of the transaction, the chief operating officer owned 65,480 shares of the company’s stock, valued at $38,200,377.20. This represents a 32.83% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. In the last three months, insiders sold 98,271 shares of company stock valued at $56,920,935. Corporate insiders own 0.33% of the company’s stock.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Board approved a 10% quarterly dividend increase to $0.47/share (payable April 15; record/ex-dividend dates disclosed), supporting yield and shareholder returns. Thermo Fisher Scientific Increases Quarterly Dividend
• Positive Sentiment: Launched TacroType™ pharmacogenetic LDT to guide tacrolimus dosing for transplant patients — a clinical product that can expand addressable market and recurring lab testing revenue if uptake is strong. Thermo Fisher Scientific Introduces New Laboratory Developed Test
• Positive Sentiment: Strategic data partnership (Datavant referenced in coverage) and other data initiatives are drawing investor interest by strengthening Thermo Fisher’s role in accelerating drug development and analytics services. This can boost higher-margin services and long-term stickiness. Valuation Check As Datavant Data Partnership Draws Fresh Investor Interest
• Positive Sentiment: Analysts remain largely bullish — multiple Buy reiterations and high price targets (e.g., William Blair, Stifel) reflect confidence in Thermo Fisher’s franchise and outlook, supporting demand for the stock. Why Analysts Are Closely Watching Thermo Fisher Scientific Inc. (TMO)
• Neutral Sentiment: Industry backdrop: market research forecasts steady mid-single-digit CAGR for laboratory informatics through 2035, suggesting a growing addressable market but gradual revenue ramp for related products/services. Global Laboratory Informatics Market Size/Share Report
• Neutral Sentiment: Coverage pieces note that TMO has slightly outperformed peers over the past year despite an overall pullback in medical-device/life-science stocks — useful context but not a catalyst by itself. How Is Thermo Fisher Scientific’s Stock Performance Compared to Other Medical Devices Stocks?
• Negative Sentiment: Near-term growth profile and valuation are mixed: analysts expect mid-single-digit organic growth and some investors may view the stock as richly valued relative to that cadence, which is a potential drag if execution or margin expansion disappoints. Thermo Fisher Scientific Inc. (TMO) Carries a Mid-Single Digit Organic Growth Forecast

Thermo Fisher Scientific Stock Performance

Shares of Thermo Fisher Scientific stock opened at $519.70 on Friday. Thermo Fisher Scientific Inc. has a 12 month low of $385.46 and a 12 month high of $643.99. The stock’s fifty day moving average price is $575.17 and its 200-day moving average price is $547.05. The firm has a market cap of $195.26 billion, a P/E ratio of 29.30, a P/E/G ratio of 2.96 and a beta of 0.93. The company has a current ratio of 1.89, a quick ratio of 1.53 and a debt-to-equity ratio of 0.67.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Thursday, January 29th. The medical research company reported $6.57 EPS for the quarter, beating analysts’ consensus estimates of $6.45 by $0.12. Thermo Fisher Scientific had a net margin of 15.05% and a return on equity of 16.92%. The business had revenue of $12.22 billion for the quarter, compared to the consensus estimate of $11.95 billion. During the same quarter last year, the firm posted $6.10 EPS. The company’s revenue for the quarter was up 7.2% on a year-over-year basis. On average, equities research analysts expect that Thermo Fisher Scientific Inc. will post 23.28 earnings per share for the current fiscal year.

Thermo Fisher Scientific declared that its Board of Directors has authorized a stock buyback program on Thursday, November 6th that allows the company to buyback $5.00 billion in outstanding shares. This buyback authorization allows the medical research company to purchase up to 2.4% of its stock through open market purchases. Stock buyback programs are generally an indication that the company’s board of directors believes its shares are undervalued.

Thermo Fisher Scientific Increases Dividend

The business also recently announced a quarterly dividend, which will be paid on Wednesday, April 15th. Shareholders of record on Friday, March 13th will be given a dividend of $0.47 per share. This is a boost from Thermo Fisher Scientific’s previous quarterly dividend of $0.43. The ex-dividend date of this dividend is Friday, March 13th. This represents a $1.88 annualized dividend and a yield of 0.4%. Thermo Fisher Scientific’s payout ratio is 9.70%.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on the stock. Weiss Ratings reissued a “hold (c)” rating on shares of Thermo Fisher Scientific in a research note on Friday, January 9th. KeyCorp raised shares of Thermo Fisher Scientific from a “sector weight” rating to an “overweight” rating and set a $750.00 price objective on the stock in a research report on Sunday, December 7th. UBS Group reissued a “neutral” rating and issued a $615.00 price objective on shares of Thermo Fisher Scientific in a research note on Friday, January 30th. Wall Street Zen downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a report on Saturday, January 31st. Finally, Barclays boosted their price objective on Thermo Fisher Scientific from $625.00 to $650.00 and gave the company an “overweight” rating in a report on Friday, January 30th. One analyst has rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and two have issued a Hold rating to the company’s stock. Based on data from MarketBeat.com, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $633.68.

About Thermo Fisher Scientific

Thermo Fisher Scientific (NYSE: TMO) is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.